Literature DB >> 10935898

Treatment of immune-mediated hemolytic anemia in dogs with cyclophosphamide.

K Burgess1, A Moore, W Rand, S M Cotter.   

Abstract

A review of 60 cases of immune-mediated hemolytic anemia (IMHA) in the dog was performed in order to characterize the disease and to identify potential prognostic indicators. Dogs ranged in age from 1 to 13 years, with a mean age of 6.5 years. The 2 most commonly affected breeds were Cocker Spaniels and Labrador Retrievers. Fifty-two of the 60 dogs tested (87%) were autoagglutination positive and spherocytes were present in 45 (75%). Forty-one (89%) of 46 patients tested positive for the presence of immunoglobulin on the red blood cell surface (Coombs assay). The most common clinical signs at presentation were lethargy, weakness, pale mucous membranes, icterus, hemoglobinuria, and anorexia. PCV less than 25% was present in 59 (98%) dogs. At the time of presentation, 35 dogs (58%) had a nonregenerative anemia, whereas 25 patients (42%) had a regenerative response. Thrombocytopenia was seen in 41 (68%) dogs. Nine of 34 dogs (26%) had a prolonged prothrombin time, 19 of 34 (56%) had a prolonged activated partial thromboplastin clotting time, and 12 of 34 (35%) had abnormal fibrinogen concentrations. All dogs received prednisone at immunosuppressive doses (2.2-4.4 mg/kg PO as a single or divided dose every 24 hours) and cyclophosphamide as primary therapy. Forty-one dogs (63%) received cyclophosphamide at 50 mg/m2 q24h for 4 days, whereas 9 dogs (15%) received an initial high dose (200 mg/m2) followed by 3 days of a lower dose (50 mg/m2 q24h). No statistical difference in survival times was found for either protocol. Thirteen dogs were treated with azathioprine in addition to cyclophosphamide and prednisone. The median survival time of dogs that received all 3 drugs was 370 days as compared to 9 days for those dogs that were treated with cyclophosphamide and prednisone alone. Thirty-one (52%) dogs died from the disease, 13 (22%) dogs were alive, and 15 (25%) dogs were lost to follow-up. The median length of survival for all dogs was 21 days. Eight dogs that were discharged from the hospital suffered a relapse (PCV < 25%).

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10935898     DOI: 10.1892/0891-6640(2000)014<0456:toihai>2.3.co;2

Source DB:  PubMed          Journal:  J Vet Intern Med        ISSN: 0891-6640            Impact factor:   3.333


  11 in total

1.  In-vitro immunosuppression of canine T-lymphocyte-specific proliferation with dexamethasone, cyclosporine, and the active metabolites of azathioprine and leflunomide in a flow-cytometric assay.

Authors:  Laura A Nafe; John R Dodam; Carol R Reinero
Journal:  Can J Vet Res       Date:  2014-07       Impact factor: 1.310

2.  Lack of evidence of a beneficial effect of azathioprine in dogs treated with prednisolone for idiopathic immune-mediated hemolytic anemia: a retrospective cohort study.

Authors:  Christine J Piek; Willem Evert van Spil; Greet Junius; Aldo Dekker
Journal:  BMC Vet Res       Date:  2011-04-13       Impact factor: 2.741

3.  Good agreement of conventional and gel-based direct agglutination test in immune-mediated haemolytic anaemia.

Authors:  Christine J Piek; Erik Teske; Martin W van Leeuwen; Michael J Day
Journal:  Acta Vet Scand       Date:  2012-02-08       Impact factor: 1.695

Review 4.  Systematic review of prognostic factors for mortality in dogs with immune-mediated hemolytic anemia.

Authors:  J W Swann; B J Skelly
Journal:  J Vet Intern Med       Date:  2015-01-13       Impact factor: 3.333

Review 5.  Canine autoimmune hemolytic anemia: management challenges.

Authors:  James W Swann; Barbara J Skelly
Journal:  Vet Med (Auckl)       Date:  2016-07-26

6.  ACVIM consensus statement on the diagnosis of immune-mediated hemolytic anemia in dogs and cats.

Authors:  Oliver A Garden; Linda Kidd; Angela M Mexas; Yu-Mei Chang; Unity Jeffery; Shauna L Blois; Jonathan E Fogle; Amy L MacNeill; George Lubas; Adam Birkenheuer; Simona Buoncompagni; Julien R S Dandrieux; Antonio Di Loria; Claire L Fellman; Barbara Glanemann; Robert Goggs; Jennifer L Granick; Dana N LeVine; Claire R Sharp; Saralyn Smith-Carr; James W Swann; Balazs Szladovits
Journal:  J Vet Intern Med       Date:  2019-02-26       Impact factor: 3.333

7.  ACVIM consensus statement on the treatment of immune-mediated hemolytic anemia in dogs.

Authors:  James W Swann; Oliver A Garden; Claire L Fellman; Barbara Glanemann; Robert Goggs; Dana N LeVine; Andrew J Mackin; Nathaniel T Whitley
Journal:  J Vet Intern Med       Date:  2019-03-07       Impact factor: 3.333

8.  Analysis of DLA-DQB1 and polymorphisms in CTLA4 in Cocker spaniels affected with immune-mediated haemolytic anaemia.

Authors:  Anna J Threlfall; Alisdair M Boag; Francesca Soutter; Barbara Glanemann; Harriet M Syme; Brian Catchpole
Journal:  Canine Genet Epidemiol       Date:  2015-06-09

9.  The use of the rapid osmotic fragility test as an additional test to diagnose canine immune-mediated haemolytic anaemia.

Authors:  Geert Paes; Dominique Paepe; Evelyne Meyer; Annemarie T Kristensen; Luc Duchateau; Miguel Campos; Sylvie Daminet
Journal:  Acta Vet Scand       Date:  2013-10-25       Impact factor: 1.695

10.  Comparison of 4 direct Coombs' test methods with polyclonal antiglobulins in anemic and nonanemic dogs for in-clinic or laboratory use.

Authors:  L L Caviezel; K Raj; U Giger
Journal:  J Vet Intern Med       Date:  2014-01-16       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.